Delivery of Therapeutic RNA to the Bone Marrow in Multiple Myeloma Using CD38-Targeted Lipid Nanoparticles

Dana Tarab-Ravski, Inbal Hazan-Halevy, Meir Goldsmith, Lior Stotsky-Oterin, Dor Breier, Gonna Somu Naidu, Anjaiah Aitha, Yael Diesendruck, Brandon D. Ng, Hagit Barsheshet, Tamar Berger, Iuliana Vaxman, Pia Raanani, Dan Peer

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Multiple myeloma (MM) is a cancer of differentiated plasma cells that occurs in the bone marrow (BM). Despite the recent advancements in drug development, most patients with MM eventually relapse and the disease remains incurable. RNA therapy delivered via lipid nanoparticles (LNPs) has the potential to be a promising cancer treatment, however, its clinical implementation is limited due to inefficient delivery to non-hepatic tissues. Here, targeted (t)LNPs designed for delivery of RNA payload to MM cells are presented. The tLNPs consist of a novel ionizable lipid and are coated with an anti-CD38 antibody (αCD38-tLNPs). To explore their therapeutic potential, it is demonstrated that LNPs encapsulating small interference RNA (siRNA) against cytoskeleton-associated protein 5 (CKAP5) lead to a ≈90% decrease in cell viability of MM cells in vitro. Next, a new xenograft MM mouse model is employed, which clinically resembles the human disease and demonstrates efficient homing of MM cells to the BM. Specific delivery of αCD38-tLNPs to BM-residing and disseminated MM cells and the improvement in therapeutic outcome of MM-bearing mice treated with αCD38-tLNPs-siRNA-CKAP5 are shown. These results underscore the potential of RNA therapeutics for treatment of MM and the importance of developing effective targeted delivery systems and reliable preclinical models.

Original languageEnglish
Article number2301377
JournalAdvanced Science
Volume10
Issue number21
Early online date12 May 2023
DOIs
StatePublished - 27 Jul 2023
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2023 The Authors. Advanced Science published by Wiley-VCH GmbH.

Keywords

  • BM niche
  • MM murine model
  • RNA therapy
  • cancer
  • lipid nanoparticles
  • multiple myeloma
  • targeted delivery

Fingerprint

Dive into the research topics of 'Delivery of Therapeutic RNA to the Bone Marrow in Multiple Myeloma Using CD38-Targeted Lipid Nanoparticles'. Together they form a unique fingerprint.

Cite this